echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The product PH94B nasal spray introduced by Ai Mai Medical for social anxiety disorder is approved for clinical use

    The product PH94B nasal spray introduced by Ai Mai Medical for social anxiety disorder is approved for clinical use

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 7, according to CDE's official website, the product PH94B nasal spray introduced by Ai Mai Medical was approved for clinical use, and the indication is anxiety symptoms of social anxiety disorder
    .

    PH94B is a potential "first-in-class", fast-acting neurosteroid candidate under development by VistaGen, which has entered a Phase 3 clinical study globally for the treatment of social anxiety disorder (SAD)
    .
    Aimmed was incubated by Cambridge Capital, which owns the development and commercialization rights of PH94B in Greater China, South Korea and Southeast Asia

    .

    Publicly available information indicates that PH94B is a potential "first-in-class", odorless, fast-acting (within about 15 minutes) synthetic neurosteroid nasal spray with the potential to treat a variety of anxiety-related disorders
    .
    In December 2019, the US FDA granted Fast Track designation to PH94B for on-demand treatment of social anxiety disorder

    .
    According to VistaGen's press release at the time, this was the FDA's first Fast Track designation for a SAD drug candidate

    .

    It is reported that PH94B is designed to be administered intranasally in microgram doses, which is fundamentally different from all current anti-anxiety drugs, including benzodiazepines
    .
    It is unique in that it activates peripheral nasal chemosensory neurons, triggering neural circuits in the brain that inhibit fear and anxiety, rather than binding to neuronal receptors in the central nervous system (CNS), thereby limiting the transport of molecules to the circulatory system and Minimize potential systemic exposure

    .
    Therefore, PH94B has a fast-acting pharmacological profile and a favorable safety profile, and does not require systemic absorption and distribution to produce a fast-acting anxiolytic effect

    .

    Social anxiety disorder is a health problem that has received much attention
    .
    According to the National Institutes of Health (NIH), social anxiety disorder is the third most common mental disorder after depression and substance abuse

    .
    People with SAD experience intense, persistent symptoms of anxiety or fear in certain social situations, such as meeting new people, going on a date, attending a job interview, answering questions in class, or talking to a cashier at a store

    .

    Currently, SAD is typically treated long-term with certain regulatory-approved antidepressants, which are slow-acting (weeks) and have limited therapeutic benefit, while antidepressants and off-label benzodiazepines have been known side effects and safety concerns
    .
    Therefore, clinically, patients have obvious needs for safe and effective new drugs

    .

    Reference materials: CDE official website, WuXi AppTec, etc.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.